Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.

Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.

Non-small cell lung cancer (NSCLC) patients that harbor epidermal growth factor receptor (EGFR) mutations benefit from receiving an EGFR-tyrosine kinase inhibitor (TKI); however, post-progression survival (PPS) after EGFR-TKI treatment has not been sufficiently studied.We retrospectively reviewed th...

Full description

Bibliographic Details
Main Authors: Yoshihito Kogure, Hideo Saka, Masahide Oki, Toshiki I Saito, Shimaa Nour Moursi Ahmed, Chiyoe Kitagawa, Kazuyoshi Imaizumi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4532435?pdf=render

Internet

http://europepmc.org/articles/PMC4532435?pdf=render

Similar Items